Search - tctmd.com

Displaying 1 - 20 of 213

Sort: Relevancy | Date

News Conference News AHA 2016

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

Michael O'Riordan

November 16, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Conference News AHA 2016

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Michael O'Riordan

November 14, 2016

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Shelley Wood

November 13, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Todd Neale

November 04, 2016

Presentation TCT 2016

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David Hildick-Smith

November 02, 2016

Presentation TCT 2016

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David R. Holmes Jr.

November 02, 2016

Presentation TCT 2016

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Presenter: Martin B. Leon, Louis A. Cannon, Sean P. Lyden

November 02, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Ganesh Manoharan

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: SENTINEL

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Alexandra J. Lansky

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: ReACT

Presenter: Giulio Guagliumi, Ik-Kyung Jang, Niels R. Holm

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: ILUMIEN III: OPTIMIZE PCI and COLOR

Presenter: Giulio Guagliumi, Ik-Kyung Jang, Ron Waksman

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) from: EXCEL and NOBLE

Presenter: Yves R. Louvard, John D. Puskas, Davide Capodanno

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Presenter: Philip M. Urban, Stephen G. Worthley, Bonnie H. Weiner

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Advertisement

Intravenous Iron, Not Oral, Improves Functional Capacity in HF Patients

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Highlights (and my Interpretations) From: SENTINEL

Highlights (and my Interpretations) From: ReACT

Highlights (and my Interpretations) From: ILUMIEN III: OPTIMIZE PCI and COLOR

Highlights (and my Interpretations) from: EXCEL and NOBLE

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content